AR033516A1 - Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo, su uso en la fabricacion de medicamentos y composiciones que los contienen - Google Patents

Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo, su uso en la fabricacion de medicamentos y composiciones que los contienen

Info

Publication number
AR033516A1
AR033516A1 ARP010101509A ARP010101509A AR033516A1 AR 033516 A1 AR033516 A1 AR 033516A1 AR P010101509 A ARP010101509 A AR P010101509A AR P010101509 A ARP010101509 A AR P010101509A AR 033516 A1 AR033516 A1 AR 033516A1
Authority
AR
Argentina
Prior art keywords
alkyl
zero
group
heteroaryl
cycloalkyl
Prior art date
Application number
ARP010101509A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR033516A1 publication Critical patent/AR033516A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ligandos de receptor tiroideo y más en particular se refieren ácidos malonámicos y derivados de los mismos, de formula (1), que son utiles en el tratamiento de obesidad, estado de sobrepeso, hiperlipidemia, glaucoma, arritmias cardíacas, trastornos cutáneos, enfermedad tiroidea, hipotiroidismo, cáncer de tiroides y trastornos y enfermedades relacionadas, tales como diabetes mellitus, arteriosclerosis, hipertension, enfermedad cardíaca coronaria, fallo cardíaco congestivo, hipercolesterolemia, depresion y osteoporosis. También se proporcionan su uso en al fabricacion de medicamentos, composiciones farmacéuticas y conjuntos para tratar dichas enfermedades y trastornos. Los compuestos de la formula (1) incluyen los isomeros del mismo, un profármaco de dicho compuesto o isomero, o una sal farmacéuticamente aceptable de dicho compuesto, isomero o profármaco; en los cuales W es (a) -O-, (b) -S-, (c) -SO-, (d) -SO2-, (e) -CH2-, (f) -CF2-; (g) -CHF-, (h) -C(O)-, (i) -CH(OH)-, (j) -NRa o (k) >C=CH2; R0 es (a) hidrogeno, (b) alquilo C1-6 sustituido con cero o un sustituyente seleccionado del grupo compuesto por (1) cicloalquilo C3-6, (2) heterocicloalquilo y (3) fenilo sustituido con cero o un sustituyente seleccionado del grupo compuesto por (i) alquilo C1-4, (ii) halogeno, (iii) -CF3 y (iv) -OCF3; (c) -C(O)Rh o (e) halogeno; (iii) R1, R2, R3, y R6 son cada uno, independientemente, (a) hidrogeno, (b) halogeno, (c) alquilo C1-8, (d) -CF3, (e) -OCF3, (f) -O-(alquilo C1-8) o (g) -CN; R4 es (a) hidrogeno, (b) alquilo C1-12 sustituido con cero a tres sustituyentes seleccionados independientemente del grupo V, (c) alquenilo C2-12, (d) alquinilo C2-12, (e) halogeno, (f) -CN, (G) -ORb, (h) -SRc, (i) -S(O)Rc, -S(O)2Rc, (k) arilo, (l) heteroarilo, (m) cicloalquilo C3-10, (n) heterocicloalquilo, (o) -S(O)2NRcRd, (p) -C(O)NRcRd, (q) -C(O)ORc, (r) -NRaC(O)Rd, (s) -NRaC(O)NRcRd, (t) -NRaS(O)2Rd, (u) -NRaRd o (v) -C(O)Rc, o bien R3 y R4 están considerados junto con los átomos de carbono a los cuales están unidos, para formar un anillo carbocíclico de formula -(CH2)i- o un anillo heterocíclico de formula -(CH2)k-Q- (CH2)i- en donde Q es -O-, -S- o -NRe; i es 3, 4, 5 o 6; k es 0, 1, 2, 3, 4 o 5; y 1 es 0, 1, 2, 3, 4 o 5; y en donde el anillo carbocíclico y el anillo heterocíclico están cada uno sustituido con cero a cuatro sustituyentes seleccionados independientemente de (a) alquilo C1-4, (b) ORb, (c) oxo, (d) -CN, (e) fenilo o (f) -NRaRg; R5 es (a) -OH, (b) -O (alquilo C1-6), (c) -OC(O)Rf, (d) F, o (e) -C(O)ORc; o bien R4 y R5 están considerados juntos con los átomos de carbono a los cuales están unidos, para formar un anillo heterocíclico seleccionado del grupo compuesto por -CRc=CRa-NH-, -N=CRa-NH-, -CRc=CRa-O-, -CRc=CRa-S-, CRc=N-NH- y -CRa=CRa-CRa=N-; R7 es (a) hidrogeno o (b) alquilo C1-6; R8 y R9 son cada uno independientemente, (a) hidrogeno, (b) alquilo C1-6, (c) arilo, o (d) halogeno; R10 es (a) (alquilo C0-1) -C(O)OH, (b) (alquilo C0-1) -C(O)ORf, (c) (alquilo C0-1)-C(O)NRcRd, o (d) (alquilo C0-1)-OH ; Ra cada vez que aparece, es independientemente (a) hidrogeno, (b) alquilo C1-6 sustituido con cero o un cicloalquilo C3-6 o metoxi; Rb cada vez que aparece, es independientemente (a) hidrogeno, (b) alquilo C1-12 sustituido con cero a tres sustituyentes seleccionados independientemente del grupo V, heteroarilo, (c) arilo, (d) heteroarilo, (e) cicloalquilo C3-10, (f) heterocicloalquilo, (g) -C(O)NRcRd, o (h) -C(O)Rf; Rc y Rd, cada vez que aparecen son cada uno , independientemente, (a) hidrogeno, (b) alquilo C1-12 sustituido con cero a tres sustituyentes seleccionados independientemente del grupo VI, (c) alquenilo C2-12, (d) alquinilo C2-12, (e) arilo, (f) heteroarilo, (g) cicloalquilo C3-10 o (h) heterocicloalquilo; o bien Rc y Rd están considerados junto con el o los átomos a los cuales están unidos, para formar un anillo heterocíclico de 3 a 10 miembros que puede contener opcionalmente un segundo heterogrupo seleccionado de -O-, -NRe-, o -S-; y en el cual el anillo heterocíclico está sustituido con cero a cuatro sustituyentes seleccionados independientemente de (a) alquilo C1-4, (b) -ORb, (c) oxo, (d) -CN, (e) fenilo o (f) -NRaRg; Re, cada vez que aparece, es (a) hidrogeno, (b) -CN, (c) alquilo C1-10 sustituido con cero a tres sustituyentes seleccionados independientemente del grupo V, (d) alquenilo C2-10 , (e) alcoxi C2-10, (f) cicloalquilo C3-10, (g) arilo, (h) heteroarilo, (i) -C(O)Rf, (j) -C(O)ORf, (k) -C(O)NRaRf o (l) -S(O)2Rf; Rf, cada vez que aparece, es independientemente (a) alquilo C1-10 sustituido con cero a tres sustituyentes seleccionado independientemente del grupo VI, (b) alquenilo C2-10, (c) alquinilo C2-10, (e) arilo, (f) heteroarilo, o (g) heterocicloalquilo; Rg, cada vez que aparece, es independientemente, (a) hidrogeno; (b) alquilo C1-6, (c) alquenilo C2-6, (d) arilo, (e) -C(O)Rf, (f) -C(O)ORf, (g) -C(O)NRaRf, (h) -S(O)2Rf o (i) cicloalquilo C3-8; Rh es (a) alquilo C1-6 sustituido con cero a un sustituyente seleccionado del grupo compuesto por (1) cicloalquilo C3-6, (2) heterocicloalquilo y (3) fenilo sustituido con cero o un sustituyente seleccionado del grupo compuesto por (i) alquilo C1-4, (ii) halogeno, (iii) -CF3 y (iv) -OCF3; (b) fenilo sustituido con cero a dos sustituyentes seleccionados independientemente del grupo compuesto por (1) alquilo C1-4, (2) halogeno, (3) -CF3 y (4) -OCF3; (c) cicloalquilo C3-6 o (d) heterocicloalquilo; el grupo V es (a) halogeno, (b) -CF3, (c) -OCF3, (d) -OH, (e) oxo, (f) alcoxi C1-6, (g) -CN, (h) arilo, (i) heteroarilo, (j) cicloalquilo C3-10, (k) heterocicloalquilo, (l) -SRf, (m) -S(O)Rf, (n) -S(O)2Rf, (o) -S(O)2NRaRf, (p) -NRaRg o (g) -C(O)NRaRf; el grupo VI es (a) halogeno, (b) hidroxi, (c) oso, (d) alcoxi C1-6, (e) arilo, (f) heteroarilo, (g) cicloalquilo C3-8, (h) heterocicloalquilo, (i) -CN, o (j) -OCF3; siempre que, cuando el sustituyente R4 sea alquilo C1-12 sustituido con cero a tres sustituyentes seleccionados independientemente del grupo V, en el cual el sustituyente del grupo V sea oxo, el grupo oxo esté sustituido en un átomo de carbono distinto del átomo de carbono C1 del alquilo C1-12; arilo, cada vez que aparece, es independientemente fenilo o naftilo sustituido con cero a cuatro sustituyentes seleccionados independientemente de (a) halogeno, (b) alquilo C1-6, (c) -CN, (d) -SRf, (e) -S(O)Rf, (f) -S(O)2Rf, (g) cicloalquilo C3-6, (h) -S(O)2NRaRf, (i) -NRaRg, (j) -C(O)NRaRf, (k) -ORb, (l) perfluoroalquilo C1-4, o (m)-COORf; siempre que cuando, el o los sustituyentes en el arilo sean -SRf, -S(O)Rf, -S(O)2Rf, -S(O)2NRaRf, -NRaRg, -C(O)NRaRf, -ORb, o -COORf, los sustituyentes Rb, Rf y Rg sean distintos de arilo o heteroarilo; heteroarilo, cada vez que aparece, es independientemente un anillo monocíclico o bicíclico de 5, 6, 7, 8, 9 o 10 que tiene 1 a 3 heteroátomos seleccionados de O, N o S; en el cual, en el anillo bicíclico, un anillo de heteroarilo monocíclico está fusionado a un anillo benceno o a otro anillo de heteroarilo; y que tiene cero a tres sustituyentes seleccionados independientemente de (a) halogeno, (b) alquilo C1-4, (c) -CF3, (d) -ORb, (e) -NRaRg, o (f) -CO2Rf; siempre que cuando el o los sustituyentes en ele heteroarilo sean -ORb, -BRaRg o -CO2Rf, los sustituyentes Rb, Rf y Rg sean distintos de arilo o heteroarilo; heterocicloalquilo, cada vez que aparece, es independientemente un anillo de cicloalquilo monocíclico o bicíclico de 4, 5, 6, 7, 8, 9 o 10 miembros que tiene 1 a 3 heteroátomos seleccionados de o, NRe o S y que tiene cero a cuatro sustituyentes seleccionados independientemente de (a) alquilo C1-4, (b) -ORb, (c) oxo, (d) -CN, (e) fenilo o (f) -NRaRg.
ARP010101509A 2000-03-31 2001-03-29 Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo, su uso en la fabricacion de medicamentos y composiciones que los contienen AR033516A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19361800P 2000-03-31 2000-03-31

Publications (1)

Publication Number Publication Date
AR033516A1 true AR033516A1 (es) 2003-12-26

Family

ID=22714346

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101509A AR033516A1 (es) 2000-03-31 2001-03-29 Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo, su uso en la fabricacion de medicamentos y composiciones que los contienen

Country Status (38)

Country Link
US (1) US20070173548A1 (es)
EP (1) EP1268404B1 (es)
JP (1) JP3866977B2 (es)
KR (1) KR20020089420A (es)
CN (1) CN1422246A (es)
AP (1) AP2002002634A0 (es)
AR (1) AR033516A1 (es)
AT (1) ATE382602T1 (es)
AU (1) AU2001237665A1 (es)
BG (1) BG107036A (es)
BR (1) BR0109625A (es)
CA (1) CA2403902C (es)
CR (1) CR6742A (es)
CZ (1) CZ20023190A3 (es)
DE (1) DE60132181D1 (es)
DZ (1) DZ3276A1 (es)
EA (1) EA200200921A1 (es)
EE (1) EE200200566A (es)
GT (1) GT200100041A (es)
HK (1) HK1052498A1 (es)
HU (1) HUP0300329A3 (es)
IL (1) IL151376A0 (es)
IS (1) IS6516A (es)
MA (1) MA26886A1 (es)
MX (1) MXPA02009702A (es)
NO (1) NO20024639L (es)
NZ (1) NZ520660A (es)
OA (1) OA12237A (es)
PA (1) PA8513801A1 (es)
PE (1) PE20011186A1 (es)
PL (1) PL358596A1 (es)
SK (1) SK13762002A3 (es)
SV (1) SV2002000357A (es)
TN (1) TNSN01048A1 (es)
TR (1) TR200202249T2 (es)
WO (1) WO2001072692A1 (es)
YU (1) YU74102A (es)
ZA (1) ZA200207444B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
PL201790B1 (pl) * 2000-02-17 2009-05-29 Bristol Myers Squibb Co Anilinopochodny ligand dla receptora tarczycy, jego zastosowanie i kompozycja farmaceutyczna
WO2002051805A1 (de) * 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Indol-derivate
GB2374009A (en) * 2001-02-12 2002-10-09 Novartis Ag Method of treating hair loss
US7279593B2 (en) 2001-08-24 2007-10-09 Karo Bio Ab Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
GB0606201D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Improved crytalline material
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
WO2009125606A1 (ja) * 2008-04-11 2009-10-15 株式会社医薬分子設計研究所 Pai-1阻害剤
US8633245B2 (en) * 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EA201170615A1 (ru) 2008-10-27 2011-12-30 Кадила Хелзкэр Лимитед Лиганды рецептора тиреоидного гормона
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010086878A2 (en) 2009-01-09 2010-08-05 Cadila Healthcare Limited Thyroid receptor modulators
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PL2695611T3 (pl) 2012-08-06 2015-03-31 Dr August Wolff Gmbh & Co Kg Arzneimittel Eprotirom do stosowania w profilaktyce i/lub leczeniu zaburzeń włosów oraz jego kompozycje
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2015156302A1 (ja) * 2014-04-09 2015-10-15 ゴールドクレスト医薬研究所株式会社 皮膚症状の改善剤、育毛剤又はスリミング剤
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
EP3634426A4 (en) 2017-06-05 2021-04-07 Viking Therapeutics, Inc. COMPOSITIONS FOR THE TREATMENT OF FIBROSIS
CN107474007B (zh) * 2017-08-28 2019-04-19 上海再启生物技术有限公司 一种制备3，6-二羟基苯二甲酰亚胺的方法
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CN112300133B (zh) * 2019-07-31 2024-07-30 深圳微芯生物科技股份有限公司 一种杂环化合物及其应用
EP3878837A1 (en) * 2020-03-11 2021-09-15 OM Pharma SA 2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069343A (en) * 1973-03-23 1978-01-17 American Home Products Corporation Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US4554290A (en) * 1983-06-17 1985-11-19 Ciba-Geigy Corporation Oxamic acid derivatives
US5061798A (en) * 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5232947A (en) * 1988-07-04 1993-08-03 Meiji Seika Kaisha, Ltd. Oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
ES2108855T3 (es) * 1992-07-21 1998-01-01 Ciba Geigy Ag Derivados de acido oxamico como agentes hipocolesteremicos.
CO5160290A1 (es) * 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
JP2003500432A (ja) * 1999-06-01 2003-01-07 ザ・ユニバーシティ・オブ・テキサス・サウスウエスタン・メディカル・センター ジフェニルエーテル誘導体を用いて脱毛症を処置する方法
US6664291B2 (en) * 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands

Also Published As

Publication number Publication date
JP2003528847A (ja) 2003-09-30
CA2403902C (en) 2007-04-24
SK13762002A3 (sk) 2004-01-08
ATE382602T1 (de) 2008-01-15
PA8513801A1 (es) 2002-02-21
PE20011186A1 (es) 2001-11-15
OA12237A (en) 2003-10-23
KR20020089420A (ko) 2002-11-29
CZ20023190A3 (cs) 2003-10-15
MA26886A1 (fr) 2004-12-20
EA200200921A1 (ru) 2003-02-27
CN1422246A (zh) 2003-06-04
ZA200207444B (en) 2003-09-17
DE60132181D1 (de) 2008-02-14
PL358596A1 (en) 2004-08-09
AU2001237665A1 (en) 2001-10-08
YU74102A (sh) 2006-03-03
BG107036A (bg) 2003-04-30
CR6742A (es) 2003-11-25
SV2002000357A (es) 2002-07-16
IS6516A (is) 2002-08-21
BR0109625A (pt) 2003-04-22
US20070173548A1 (en) 2007-07-26
CA2403902A1 (en) 2001-10-04
HK1052498A1 (zh) 2003-09-19
IL151376A0 (en) 2003-04-10
AP2002002634A0 (en) 2002-09-30
GT200100041A (es) 2002-03-22
DZ3276A1 (fr) 2001-10-04
TNSN01048A1 (fr) 2005-11-10
EP1268404B1 (en) 2008-01-02
WO2001072692A1 (en) 2001-10-04
HUP0300329A3 (en) 2004-08-30
NZ520660A (en) 2004-03-26
TR200202249T2 (tr) 2003-01-21
NO20024639D0 (no) 2002-09-27
NO20024639L (no) 2002-09-27
HUP0300329A2 (hu) 2003-07-28
JP3866977B2 (ja) 2007-01-10
MXPA02009702A (es) 2003-03-27
EP1268404A1 (en) 2003-01-02
EE200200566A (et) 2004-06-15

Similar Documents

Publication Publication Date Title
AR033516A1 (es) Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo, su uso en la fabricacion de medicamentos y composiciones que los contienen
KR102602947B1 (ko) 제약 화합물
EP3082802B1 (en) Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use
ES2378776T3 (es) Derivado de ácido aminocarboxílico y uso medicinal del mismo
WO2016071283A1 (en) Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase
TWI662015B (zh) 稠合三環γ－胺基酸衍生物、其製備方法及其在醫藥上的應用
WO2015150097A1 (en) Indole derivatives for use in medicine
CA2783466C (en) Amyloid binding agents
AR037484A1 (es) Un compuesto derivado de amino-triazolopiridina, un medicamento que contiene uno o mas de los compuestos, un proceso para la preparacion del compuesto y el uso del compuesto
ES2534345T3 (es) Bitionol como agente antiangiogénico
AU2016324013B2 (en) Substituted 1H-indole-2-carboxamide compounds as indoleamine-2,3-dioxygenase inhibitors
AR048789A1 (es) Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
JP2020529994A5 (es)
RU2008125040A (ru) ПРОИЗВОДНЫЕ АРИЛ-ИЗОКСАЗОЛ-4-ИЛ-ИМИДАЗО[1.5-a]ПИРИДИНА
JP2017522304A5 (es)
JP2004518767A5 (es)
KR20150130392A (ko) 구아니디노벤조산 에스테르 화합물
RU97114793A (ru) 2-аминоинданы в качестве селективных лигандов допамина д3
JP2005508969A5 (es)
AR039780A1 (es) Ligandos receptores de melanocortina
DE60130031T2 (de) Dihydronaphthalinderivat verbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten
WO2020027150A1 (ja) ベンゼン誘導体
WO2001021583A1 (fr) Derives d'acide hydroxamique, procede de production desdits derives et medicaments contenant lesdits derives comme principe actif
AR047337A1 (es) Ligandos de los receptores de acetilcolina nicotinicos
RU2002102495A (ru) Новые производные ксантона, их получение и применение в качестве лекарственного средства

Legal Events

Date Code Title Description
FB Suspension of granting procedure